Test for pregnancy in medical setting before starting isotretinoin, then can be done at ho ...

The FDA approved modifications to the iPLEDGE Risk Evaluation and Mitigation Strategy that permit patients to take a pregnancy test outside of a medical setting during and after isotretinoin treatment ...

Q: I’m dealing with hormonal acne. What’s the best way to clear it up?. “I’m a big fan of topical probiotics for hormonal acne—they’re a game changer! They calm redness, strengthen the skin barrier ...

March 9, 2006 (San Francisco) — The largest and arguably most complex risk-management program ever undertaken by the US Food and Drug Administration is sparking a commensurate measure of controversy — ...

Modifications to the iPLEDGE Risk Evaluation and Mitigation Strategy aim to reduce challenges for patients, prescribers and ...

An FDA advisory committee on Wednesday voted 17-4 (with one abstention) to recommend removing a "lockout period" from a risk evaluation and mitigation strategy (REMS) for isotretinoin prescribing that ...

Please provide your email address to receive an email when new articles are posted on . Pregnancies, abortions and fetal defects associated with isotretinoin exposure continue to be a problem even ...

The Food and Drug Administration has approved system changes to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program for isotretinoin products. The system changes will go into effect ...

(TNS) -- It has been 13 years since the U.S. Food and Drug Administration took a bold step to prevent birth defects caused by the only drug that can cure severe acne. Women were still getting pregnant ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." When Grace, 30, a data analyst in North Carolina, got her precious first prescription of isotretinoin, ...

WASHINGTON The Food and Drug Administration announced that Covance, the developer of the iPLEDGE risk management program has fully implemented the program revisions approved by the FDA on Oct. 3. The ...